Brian Sean Bingham
About Brian Sean Bingham
Brian Sean Bingham is the Associate Director of National Accounts, Hematology Oncology at Bristol Myers Squibb, overseeing the Great Lakes Region.
Company
Brian Sean Bingham is currently employed by Bristol Myers Squibb, a prominent biopharmaceutical company. He serves as the Associate Director, National Accounts, Hematology-Oncology in the Value, Access, and Payment department. His leadership scope includes the Great Lakes Region, where he oversees strategic directions across Michigan, Illinois, and Wisconsin.
Title
Brian Sean Bingham holds the title of Associate Director, National Accounts, Hematology Oncology. His responsibilities include leading health plan and health system business strategies and managing strategic accounts in key regions.
Education and Expertise
Brian Sean Bingham studied at the University of Michigan. He possesses extensive experience in managing diseases such as oncology, hematology, inflammatory disease, and cardiology, making him well-versed in the complexities of these medical fields.
Professional Background
Brian Sean Bingham has a long-standing career with Bristol Myers Squibb. He first joined the company in 1998 as an Executive Territory Manager in the Greater Detroit Area, spending four years in that role. He then served as District Business Manager from 2002 to 2007, followed by a seven-year tenure as Executive District Business Manager from 2007 to 2014. Subsequently, he was a Regional Account Executive Payer, specializing in Specialty Pharmacy and Organized Customers in the Tri-Cities, Michigan Metropolitan Area, for six years until 2020. In 2019, he also contributed as the Value, Access, and Payment Payer Brand Preceptorship for the Hematology Franchise in Princeton, NJ for nine months.
Industry Experience
Brian Sean Bingham brings profound experience in dealing with strategic accounts related to community oncology, health systems, payers, and State Medicaid. His depth of knowledge in value, access, and payment frameworks, particularly in the fields of oncology and hematology, underscores his expertise in the biopharmaceutical industry.